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a b s t r a c t
As biomarker discovery takes centre-stage, the role of immunohistochemistry within that process is
increasing. At the same time, the number of antibodies being produced for ‘‘research use’’ continues to
rise and it is important that antibodies to be used as biomarkers are validated for speciﬁcity and sensi-
tivity before use. This guideline seeks to provide a stepwise approach for the validation of an antibody for
immunohistochemical assays, reﬂecting the views of a consortium of academic and pharmaceutical
based histopathology researchers. We propose that antibodies are placed into a tier system, level 1–3,
based on evidence of their usage in immunohistochemistry, and that the degree of validation required
is proportionate to their place on that tier.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
The term ‘‘biomarker’’, in its broadest sense, deﬁnes any biolog-
ical or physiological entity that is used to identify disease, guide
targeted therapy or monitor for re-occurrence. In histopathology,
immunohistochemistry (IHC) is routinely used for diagnosis [1]
and with the advent of the patient selective cancer therapy trastuz-
amab for breast [2] and gastric cancer [3], or demonstration of
C-kit for gastrointestinal stromal tumours targeted therapy [4], it
is being used as a decision making tool to ascertain those patients
who are most likely to beneﬁt from treatment. Furthermore, the
possibility of using antibodies to detect speciﬁc EGFR mutations
as a guide for the administration of EGFR-targeted therapies in
non-small cell lung cancer could result in IHC being used as a quick
and cost effective replacement for the DNA sequencing based
methods presently employed [5].
The development of an IHCbiomarker can begin at the same time
as the association of gene expression with a disease points toward
development of a drug. Thus microarray data, next-generation
sequencing and sometimes in situ hybridisation can provide the tar-
gets for biomarker selection and point to the need to either select or
make an antibody to that target [6]. Whether ‘home grown’ or se-
lected from existing commercial offerings it is of critical importance
that the biomarker antibody is validated as speciﬁc for its target and
of sufﬁcient sensitivity toallow IHCdemonstrationover the required
dynamic range demanded by the pathology it will be used to iden-
tify. The chief beneﬁt of early validation is that the IHC based
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biomarker can be used with conﬁdence during the drug develop-
ment process to assist in understanding the target better, to segre-
gate pathologies most likely to beneﬁt from therapy and
potentially to become the method by which this selection is made
in the clinical setting. In the wider context of research pathology
where IHC is frequently employed, thorough antibody validation
will ensure that quality reagents are used. Regrettably, information
supplied in many academic publications [7] and contained in com-
mercial data sheets is not sufﬁcient to allow conﬁdence to be built
into an antibody and on-going validation is required [8]. Thus, time
needs to be expended by others tomake good the information gap, a
process that is inherently inefﬁcient when an antibody is shown to
be unacceptable for use. The purpose of this guideline, similar to
guidelines published recently on tissue microarrays [9] and the ef-
forts of the Clinical Laboratory Standards Institute for standardisa-
tion [10] is therefore to provide a tiered approach to the validation
of an antibody for use as an IHC biomarker in formalin-ﬁxed, paraf-
ﬁn-embedded (FFPE) tissue and to promote this being undertaken
before it is used as a biomarker of disease. These guidelines are
equally applicable to the validation of an antibody for use in frozen
tissue IHC and wholemount in situ staining protocols. A summary
of the key features of these guidelines is contained in Table 1.
2. Steps to validation
2.1. Step 1: Understand target
It is vital before attempting any validation that a full literature
review of the target is undertaken. Firstly, this will build a picture
of when and where expression is to be expected and, should IHC
have been attempted previously, can point to antibodies that could
be evaluated. Secondly, where post-translational modiﬁcations or
splice variants have been described, this information can be used
to predict detection of multiple bands in Western blotting and thus
antibodies that would have been rejected as ‘‘non-speciﬁc’’ will be
kept. Databases such as OMIM [11], Uniprot [12] or Genecards [13]
are particularly useful for gathering such information. Note, how-
ever, that online resources that are based on mRNA expression
can provide spurious results, since the levels of protein and mRNA
do not always correlate [14,15]. The biological relevance of the
target is important, as this can give an indicator on the likely
sub-cellular localisation of the target and as a consequence any
non-speciﬁc interactions can be identiﬁed. For example, a tran-
scription factor is likely to have a nuclear localisation and therefore
a cell surface staining pattern would be spurious.
2.2. Step 2: Identify cell and tissues
Control material is critical to the validation and can take several
forms. Positive and negative cultured cells, identiﬁed through the
literature search, can be used for Western blotting, ﬂow cytometry
(for membrane bound targets) and the preparation of FFPE cell
blocks for IHC [16,17]. When selecting positive and negative con-
trol cell lines it is of great value to determine the expression of
the required biomarker using more than one assay format e.g. con-
ﬁrming positive or negative biomarker expression of cells by ﬂow
cytometry before using as an IHC control. This builds conﬁdence
in the expression proﬁle of control cell lines and forms part of
the validation process. It is important when FFPE cell blocks are
made, that cells are spun down lightly to retain cytology, ﬁxed in
the same buffers and times as tissue controls, suspended in agarose
and processed in the normal manner to mimic the tissue that they
are validating. The standardisation of this process is equally essen-
tial, since a variety of ﬁxation regimes and processing methods are
referred to in the literature. Once individually processed, the crea-
tion of a cell line microarray (CMA) [18,19] can assist not only in
determining reaction across multiple cell lines, but also as a quality
control check of the IHC once the biomarker antibody has been val-
idated [20]. Using cell lines in this manner has already been vali-
dated in the clinical setting [21].
The use of cell culture lines can also prove beneﬁcial particu-
larly where they can be manipulated by transfection to introduce
different ‘dose’ levels of the target in otherwise weakly positive
or negative cell lines. As transfection efﬁciency rarely reaches
100%, a proportion of the cells should remain negative or weakly
stained for the target in question which can be useful in differen-
tiating IHC signal from background noise. This also remains the
case where RNA is used to knockdown positive cell lines. Indeed,
a recent confocal study on cell lines has demonstrated that in
765 proteins studied using 75 antibodies that siRNA silencing
can be effective in 80% of cases [22].
Whilst cell lines can provide an indicator of the expression, par-
ticularly in comparison to non-IHC methods, the use of positive/
negative control tissue is essential for the full validation of the
antibody and evaluation of non-speciﬁc binding to other tissue
components. The literature and online reviews should point to po-
tential positive and negative tissues. However, as expression levels
are often modulated in disease then it may be important to include
a range of pathologies and, preferably, matched normal tissue.
Prior to selecting positive material, the quality of the tissues needs
to be assessed and it is therefore recommended that a panel of
Table 1
Step-by-step guide to validating an antibody.
Step Special considerations
Understand target Full literature review
Note the biological relevance and expected sub-cellular localisation
Identify cells and tissues Identify or create positive/negative cell lines
Identify positive/negative control tissues
Check the quality of the control material with standardised antibodies and ensure it matches the quality of the test material
Choose an appropriate IHC method Use a commercially prepared and validated kit
Test multiple retrieval conditions to optimise the staining
Consider the use of automation
Identify level of validation required Identify which tier of validation is appropriate
Tier 1: Well known antibody with high quality literature evidence
Tier 2: Well known antibody used in an alternative species or unvalidated tissue
Tier 3: Unknown antibody. Inconsistent/No literature evidence
Control of IHC Use the same controls that were used for validation when performing test samples
Test antibody in at least one other non-IHC method
Use negative controls, such as omission of primary antibody or isotype-matched controls to identify any background staining
Publication of results Include appropriate control material either within publication or as supplementary material
MISFISHIE guidelines should be used
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characterised generic antibodies, preferably in vitro diagnostic re-
agents, are run on the tissue to validate it. For example, desmin
for muscle (e.g. Clone DE-R-II), cytokeratin for epithelial tissue
(e.g. Clone AE1/3), neuroﬁlament for neural tissue (e.g. 2F11).
Some targets, such as phosphoproteins, require special consid-
eration in tissue choice as ischaemia can dramatically reduce the
level of target available for IHC demonstration [23]. Due to clinical
constraints, there is little opportunity to control warm ischaemia
but samples should be immersed in formalin (or otherwise pre-
served within 15–30 min of removal from the patient). A pan-
phosphotyrosine antibody can have utility in determining whether
a tissue sample is unlikely to demonstrate phospho-epitopes [24].
Holding tissue after ﬁxation in ethanol does not appear to have any
adverse effects on the levels of phosphoproteins demonstrable by
IHC [25], however, it is recommended that a standardised time in
ethanol is used per study to ensure comparable results. These fac-
tors, of course, can put constraints of the application of this type of
antibody once the validation process has been completed.
As with cell lines the preparation of TMAs is very useful as this
will maximise IHC data whilst ensuring that the technical param-
eters are uniformly applied to the tissue set. It has been reported
that some antigens, i.e., CD3 [26], ER [27] and pSMAD2 (WH per-
sonal observation), deteriorate in cut sections which has recently
been proposed to be due to presence of water within inadequately
processed tissue specimens [28]. To avoid this becoming a compli-
cating factor in the validation of a new antibody, sections should be
cut and used within a standard period of time. The practice of cut-
ting sections and coating with parafﬁn wax alone to minimise sur-
face oxidation/hydrolysis has not been routinely shown to be of
beneﬁt [27,29], however the storage of tissue microarray sections
at 20 C without coating in wax has been favourably tested to
room temperature storage over a 6 month period (Kampf,
unpublished observations).
2.3. Step 3: Choose an appropriate IHC method
The expected expression level of the target will often determine
the choice of detection method. For example, the Labelled StreptA-
vidin Biotin (LSAB) technique may not have the sensitivity for
some antigenic expression, where use of polymer systems or tyra-
mine ampliﬁcation may be required in its stead [30,31]. The use of
esoteric detection methods should be avoided as these may lead to
problems of reproducibility. Care should also be taken to approach
variation of the technique systematically, to employ the same
reagent batches throughout the validation and to record staining
results using a standardised reporting template, such as the ‘H’
score system [32], so that run-to-run comparisons can be made.
Unless the literature review indicates otherwise, the compari-
son of pH6 and pH9 heat induced epitope retrieval (HIER) buffers
together with incubation of the antibody at two dilutions/concen-
trations should provide an initial indication of which combination
is worth pursuing further. The addition of an enzyme digestion re-
trieval at this stage may reveal antigens that are particularly sensi-
tive to protease digestion, such as alpha smooth muscle actin,
clone 1A4 [33]. If these assessments fail to provide adequate stain-
ing then consideration should be given to using a combination of
protease digestions and HIER or no retrieval at all. In all cases,
the staining pattern received should be compared to that described
in the literature for alignments to tissue positivity, cellular positiv-
ity and sub-cellular localisations, as a variation of the expected
staining pattern more often indicates a non-speciﬁc binding of
the antibody rather than an interesting scientiﬁc observation.
Other variations that can be tested include the time and tempera-
ture of HIER, primary antibody incubation and range of antibody
dilution/concentration. Alternative ﬁxatives can be investigated
but can only be applied to prospective collections, as the majority
of tissue collections in both research and clinical arena’s utilise
neutral buffered formaldehyde.
The above principles apply whether performing manual or
automated staining. The use of semi- or fully-automated staining
systems has revolutionised immunohistochemistry particularly in
the clinical arena, where in vitro diagnostic antibodies and staining
kits are employed to provide fast and reproducible staining which
is computer controlled and monitored. Thus, automated IHC has
signiﬁcant advantages and can provide the researcher with repro-
ducibility, sensitivity, a reduction in error rate and improvements
in slide tracking and monitoring. However, the cost of such sys-
tems can be prohibitive to smaller research laboratories running
lower throughput assays and there is no evidence that an auto-
mated assay outperforms a well validated manual assay in this
setting.
2.4. Step 4: Identify level of validation required
We recommend the following 3 tiers of validation:
Level 1: Where an antibody is to be applied to tissue for which
there is reliable IHC literature and it has become well established
and trusted; an example are antibodies that recognise Ki67 [34],
then validation can be as straightforward as reproducing the ex-
pected result on positive and negative tissues to gain an appropri-
ate signal/noise ratio.
Level 2: Where an antibody has previous cited literature for IHC
that is reliable, but where the tissue or preparation is different to
that previously described, then validation should be undertaken
using positive control material as detailed in Step 2 (above). For
example, the application of HER2 in gastric cancer, where it was
originally validated in breast cancer, would fall under this cate-
gory. The resulting IHC should be carefully compared for consis-
tency of staining and, where necessary, the dilution/
concentration of the antibody adjusted to give optimal signal/noise
ratio in the new samples. Where an inconsistent pattern appears at
this point, the validation should be taken to Level 3, as it may be
that the previous published data is unreliable [35].
Level 3: This level of validation is required where little or no reli-
able IHC data is available. The most extreme example of this would
be a home-grown antibody, however, an antibody where there is
no evidence on the datasheet that it has been tested by immuno-
histochemistry would also fall under this category. Similarly, with
experience, antibodies designated by the supplier as appropriate
for IHC, may also fall into this category where insufﬁcient data is
provided to demonstrate this, or where that data is inconsistent
with the knowledge gained under Step 1 above.
In this instance validation should proceed in a stepwise fashion
to build conﬁdence in the performance of an antibody. Where sev-
eral antibodies are available then these can be taken through the
process together and selectively discarded if they fail at a valida-
tion step. The use of ‘‘sibling antibodies’’, where multiple antibod-
ies are prepared to the same target, as utilised by the Human
Protein Atlas and Atlas of Protein Expression projects [36,37], can
add conﬁdence in the data quality and thus may be considered
as a Level 2 validation, but only where both antibodies provide
the same staining pattern.
Before running the antibody in IHC, it must be tested on at least
one other non-IHC method. As a minimum, this should be an in-
houseWestern blot, where the protein is resolved from a cell or tis-
sue lysate or from formalin-ﬁxed tissue sections [38]. The use of
Western blots generated against recombinant protein alone is
not recommended as it unlikely to demonstrate the full range of
potential cross-reactivities. Flow cytometry against panels of
known positive cell lines can demonstrate speciﬁcity and a degree
of cross-reactivity of cell membrane antibody targets. Ultimately,
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the antibody may be used in an immunoprecipitation experiment,
cut out and resolved by mass spectrometry for speciﬁcity [39,40].
Before running the antibody on tissues, it must be tested on puta-
tive positive and negative control material, since determination of
speciﬁcity by Western blot does not guarantee speciﬁcity after the
target has been subjected to formalin ﬁxation and antigen retrie-
val. The positive tissues should establish that the correct cell type,
compartment and staining intensity is present, whilst negative tis-
sues are valuable in conﬁrming the non-reactivity of the antibody
and adjusting signal/noise ratio if background staining is encoun-
tered. When used in combination with positive or negative cell
lines, either inherent or induced, the speciﬁcity of the antibody will
be conﬁrmed. Once an antibody has passed through these valida-
tion steps it should be used on TMA preparations of relevant tis-
sues to conﬁrm its sensitivity and speciﬁcity on a sample set
representative of its ultimate use.
2.5. Step 5: Control of IHC
Once an antibody has been successfully validated, run controls
must be used to conﬁrm that acceptable results are generated. In
each IHC runbothpositive andnegative controls should be included.
When possible the positive control should match the tissue un-
der investigation and should contain a moderate level of target.
Thus, if conditions of an IHC run are sub-optimal the intensity of
staining in the positive control will be noticeable and the investi-
gation of potential reasons for this can begin. For clinical antibody
based biomarkers, such as HER2 [41,42], the incorporation of a
range of control tissues or FFPE cell blocks preparations can be
obligatory to conﬁrm that sensitivity levels are being met.
Negative controls provide information on aberrant staining due
to the presence of endogenous substances, such as endogenous bio-
tin or peroxidase, or other non-speciﬁc staining due to bindingof the
primary and/or secondary reagents. Thus they control both the
staining method as well as the validated antibody. Omission of the
primary antibody only and replacement with primary antibody dil-
uent, controls only the stainingmethod. For control of amonoclonal
primary antibody, an isotype matched control fraction should be
usedwhereas controlling for afﬁnity-puriﬁed polyclonal antibodies,
an afﬁnity-puriﬁed, species-matched polyclonal or incubation in
non-immune serum should reveal general non-speciﬁc staining.
However, it should be noted that the use of the latter control can it-
self give rise to this type of staining because of themilieu of proteins
present in its composition. Ultimately, an isotypematched antibody
for a target that is absent from the tissue, for example GFP or BrdU,
can be used, but these are not always available.
The employment of blocking peptides in an IHC reaction should
be carefully considered. Whilst suppression of signal is evidence
that the primary antibody is interacting with the tissue this cannot
be used as prima facie evidence of speciﬁcity as cross-reacting
substances will also suppressed [43]. Abolition of IHC signal by a
phosphatase treatment step can be used to demonstrate in the
validity of phospho-speciﬁc antibodies.
2.6. Step 6: Publication of results
To avoid the need for revalidation of already published material
or to enable validation to be taken further, all IHC publications
should include information that clearly states the source of anti-
body employed and the conditions under which it was used;
Table 2sets out an example of this. At this time, only the Journal
of Comparative Neurology [44], and more recently Endocrinology
[45], speciﬁcally request their authors to state their antibody’s
speciﬁcity and validations. Indeed, the Journal of Comparative
Neurology has gone a step further to publish a free online database
of all antibodies submitted to the journal since 2006 [46]. To this
end it is strongly recommended that the MISFISHIE guidelines for
reporting in situ hybridisation and IHC is used [7] and it should
be noted that these guidelines also include requirements for stand-
ardised scoring systems and imaging. Furthermore, reporting of
the conditions on an open access site following publication, such
as AntibodyPedia [47,48] can only increase the use of antibodies
for biomarker validation and improve the quality of the publica-
tions brought from their use.
3. Summary recommendations
IHC has become the ‘special stain’ of histopathology. It has an
important diagnostic role, and is increasingly used as a biomarker
to phenotype tumours leading to targeted drug therapy. Unlike
some tinctorial staining methods, the techniques that are em-
ployed in IHC are relatively few and reproducible when undertaken
in a careful manner. However, whilst antibodies used as biomark-
ers for targeted drug therapy are, of necessity, validated and ap-
proved by regulatory bodies, the evolution of many antibodies
that are now accepted for research use in IHC has been through a
path akin to survival of the ﬁttest. There are thousands of bio-
marker candidate antibodies available that could be used for IHC,
but few carry with them any evidence of rigorous validation. Fur-
thermore, many antibodies have been used in publications without
due consideration of the necessity of validation or indeed the
recording of methods used in sufﬁcient detail to allow the work
to be reproduced [7]. This in turn has led to false starts in IHC
based biomarker identiﬁcation and wasted research effort. With
these realities in mind we have provided guidelines as the basis
of best practice for biomarker antibody validation. Our recommen-
dations are based on a stepwise approach by which conﬁdence is
gradually built in an antibody and end with the information ac-
quired during the validation process being shared with the scien-
tiﬁc community to avoid the need for its repetition. Adoption of
the guidelines should assist biomarker development and also ben-
eﬁt the IHC community as a whole, enabling the identiﬁcation of
antibodies that will make both diagnostic and clinical differences.
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